Format

Send to

Choose Destination
See comment in PubMed Commons below
Curr Opin Biotechnol. 2012 Dec;23(6):941-7. doi: 10.1016/j.copbio.2012.04.002. Epub 2012 May 3.

Genome-based bioprospecting of microbes for new therapeutics.

Author information

  • 1Department of Biotechnology, Norwegian University of Science and Technology, Trondeim, Norway. sergey.zotchev@nt.ntnu.no

Abstract

Bioprospecting of natural sources for new medicines has a long and successful history, exemplified by the fact that over 50% of all drugs currently on the market are either derived from or inspired by natural products. However, development of new natural product-based therapeutics has been on the decline over the past 20 years, mainly owing to frequent re-discovery of already known compounds coupled with high costs for screening, characterization and development. With the onset of the genomic era allowing rapid sequencing and analysis of bacterial and fungal genomes, it became evident that these organisms possess 'hidden treasures' in the form of gene clusters potentially governing biosynthesis of novel biologically active compounds. This review highlights current progress in mining for and expression of these gene clusters, which may revolutionize the drug discovery pipelines in the near future.

Copyright © 2012 Elsevier Ltd. All rights reserved.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk